HRS-2398

Main study objectives: To evaluate the tolerability of HRS2398 combined with Adebelimumab injection in patients with advanced solid tumors; To determine the recommended Phase II clinical dose (RP2D) of HRS2398 combined with Adebelimumab injection in patients with advanced solid tumors; To evaluate the efficacy of HRS2398 combined with Adebelimumab injection in patients with advanced solid tumors. Secondary study objectives: To evaluate the efficacy of HRS2398 combined with Adebelimumab injection in patients with advanced solid tumors (for the dose exploration phase); To evaluate the safety and pharmacokinetic (PK) characteristics of HRS2398 combined with Adebelimumab injection in patients with advanced solid tumors; To evaluate the immunogenicity characteristics of Adebelimumab. Exploratory study objectives: To evaluate the correlation between biomarkers and efficacy; To explore the effect of HRS2398 on the QT interval of patients with advanced malignant tumors; To explore the drug metabolism characteristics of HRS2398 in the plasma of patients with advanced malignant tumors.

Main purpose: To determine the dose-limiting toxicity and maximum tolerated dose of HRS2398 monotherapy in patients with advanced malignant tumors, and to clarify the dosage and dosing regimen for subsequent clinical trials. Secondary purpose: To evaluate the safety and efficacy of HRS2398; to analyze the pharmacokinetic characteristics of HRS2398 and its metabolites; to explore the food effect of HRS2398. Exploratory study purpose: To preliminarily explore the relationship between gene mutation and protein expression status and efficacy; to analyze the relationship between gene mutation and clinical efficacy and drug resistance mechanism.